MYC and chronic myelogenous leukemia, BCR-ABL1 positive: The CML cell line K562 has amplifications in the c-myc and l-myc oncogenes but is resistant, compared to all the other leukemia and lymphoma cell lines so far tested, to Chk1 inhibitors as single agents.